EyePoint Pharmaceuticals (NSDQ:EYPT) said this week that the Centers for Medicare and Medicaid Services approved transitional pass-through status and reimbursement of its dexamethasone intraocular suspension, Dexycu.
The FDA-approved product is designed to treat inflammation following cataract surgery using a single, intraocular dose of long-acting dexamethasone.
Get the full story at our sister site, Drug Delivery Business News.
The post EyePoint nabs CMS reimbursement for Dexycu cataract surgery drug appeared first on MassDevice.
from MassDevice https://ift.tt/2M6cORu
Cap comentari:
Publica un comentari a l'entrada